Oncology
Deep understanding across multiple disciplines.
Aixial Group
A CRO with an oncology focus since 1999
We are focused on serving the biopharma/biotech market and strive to be a consultative and proactive oncology CRO partner. Our customised solutions are designed around the individual needs of each of our biopharma clients.
Our work in trial designs
We excel in delivering trials evaluating the latest advances in investigational therapies. Our team is well versed in a plethora of trial designs including dose escalation both biomarker based and not, blind/double blind, cross over trials and others. Our experience enables our ability to help sponsors develop or deliver a personalized approach to medicine and an increased efficiency in investigational product development.
Our people, company culture, and can-do attitude, combined with our unique expertise in oncology and advanced technology, set us apart from the competition. We aim to be more than just a vendor by adding value to the clinical development of our biopharma clients’ emerging therapies. We take pride in our commitment to delivering high-quality service.
We take pride in our commitment to delivering high-quality service.
- Expertise in advanced trials designs, i.e., accelerate dose escalation modalities, adaptive, basket, umbrella, etc
- A team with 100% oncology experience
- Dedicated teams to early and later phase trials
- Understanding the risks and contingencies to delivering any project on time
- Technology enabled
- Proactive partnership approach
- Close communication between our team, sites and sponsor
Helping you suceed in your project
Examples of our intricate trial design experience
Interaction designs
Defined as enrollment of marker + and – patients with randomized to targeted vs. non-targeted therapy
Enrichment designs
Defined as enrollment of marker + patients only, with or without randomization
Adaptive enrichment designs
Defined as adaptable enrollment during trial from full population to patients who seem to benefit from product under study
Marker strategy designs
Defined as patients randomize to treatment strategy: based on biomarker status vs. not based on biomarker status (e.g., physician’s choice)
Master protocols
Basket trials, umbrella trials, platform trials, etc
How can we support your next project?
Whether you’re looking for a protocol review or a proposal,
simply reach out to us by filling our request for proposal.
Insights
OTHER WAYS WE SUPPORT YOU